New York, USA – December 22, 2020 – Recently, BOC RNA announced the expansion of its existing cooperation scope, including the development and commercialization of RNAi therapeutic drugs. The company will use its latest progress in targeted delivery of siRNA drugs and its established capabilities to deepen the development of RNAi drugs for tumors and neurological diseases.
Safe and effective siRNA delivery has always been a key challenge in the field of therapeutic RNAi. The siRNA conjugate delivery platform developed by BOC RNA scientists can overcome this challenge. “This technology is different from the lipid nanoparticle siRNA delivery system used by most RNAi therapy companies. And we believe that this will be one of the most promising solutions in the field of RNAi therapy,” said Dr. Sarah, Chief Scientist of BOC RNA Drug Delivery Platform.
siRNA conjugation modification is a customizable and powerful tool that can solve the problem of RNAi delivery and can create a variety of new therapies. This efficient delivery solution is a powerful complement to BOC RNA’s advanced siRNA drug development service portfolio, making the company the preferred partner of large biotech and pharmaceutical companies interested in creating RNAi therapeutics.
RNA interference (RNAi) is a natural process of gene silencing in cells, which represents one of the most promising and rapidly developing fields in biology and drug development today. As an emerging drug, small interfering RNA (siRNA), a molecule that mediates RNAi, can effectively silence the messenger RNA (mRNA) of certain genes to suppress the expression of disease-causing genes, thereby treating the disease.
About BOC RNA
BOC RNA is a biotechnology company focused on RNA drug research and development. It is committed to combining RNA therapy concepts with the latest drug delivery technologies to prevent and treat serious human diseases. BOC RNA uses its technology platform to design and develop chemically modified and biologically conjugated siRNAs. These conjugates specifically target cells of interest with higher stability and specificity.
For more information, please visit https://rna.bocsci.com.